Objective: The objective of this prospective randomized phase III trial was to compare paclitaxel plus carboplatin (PC) versus topotecan plus carboplatin and paclitaxel (TPC) in women with suboptimal stage III (residual tumour >1 cm) or stage IV ovarian cancer to evaluate the survival rate and toxicities. Methods: Eligible for the study were patients aged at least 18 years old with histological/ cytological diagnosis of FIGO stages III (residual tumour P1 cm after primary surgery) – IV epithelial ovarian cancer. Patients were randomized to iv PC on day 1, every 21 days or iv topotecan daily for three days and PC on day 3, every 21 days. Results: The intention to treat population was made of 326 patients in total, 170 in the PC group and 156 in the TPC group. The life table estimates of survival probabilities at one, three and five years were, respectively, 0.94 (95% CI: 0.88–0.97), 0.53 (95% CI: 0.44–0.62) and 0.32 (95%CI: 0.23–0.42) in the PC group, and 0.92 (95% CI: 0.86–0.95), 0.52 (95% CI: 0.42–0.61), and 0.32(95%CI: 0.22–0.43) in the TPC group (log-rank test at 5 years: ns). The results of the survival analysis based on Cox regression model showed no statistically significant differences between groups (p-value: ns). The number of subjects with at least one event with possible relationship to study medication was 151 (88.8%) in the PC group and 139 (89.1%) in the TPC group (p = ns). Results: In the PC group, 79 patients (23.6%) experienced at least one Adverse Event (AE) graded as severe and 16 patients (4.8%) at least one life-threatening AE, whilst in the TPC group, the number of patients who presented at least one severe or life-threatening AE was 86 (24%) and 37 (10.3%), respectively. Conclusion: The results of the present study show that the addition of topotecan to a standard paclitaxel/carboplatin regimen in the treatment of advanced epithelial ovarian cancer did not result in significant advantages in terms of survival rate. A slightly worse toxicity profile for TPC was observed

Paclitaxel/carboplatin versus topotecan/paclitaxel/carboplatin in patients with FIGO suboptimally resected stage III–IV epithelial ovarian cancer a multicenter, randomized study / G. Bolis, G. Scarfone, F. Raspagliesi, G. Mangili, S. Danese, P. Scollo, D. Lo Russo, A. Villa, P. D. Aimone, G. Scambia. - In: EUROPEAN JOURNAL OF CANCER. - ISSN 0959-8049. - 46:16(2010), pp. 2905-2912.

Paclitaxel/carboplatin versus topotecan/paclitaxel/carboplatin in patients with FIGO suboptimally resected stage III–IV epithelial ovarian cancer a multicenter, randomized study

G. Bolis
Primo
;
G. Scarfone
Secondo
;
2010

Abstract

Objective: The objective of this prospective randomized phase III trial was to compare paclitaxel plus carboplatin (PC) versus topotecan plus carboplatin and paclitaxel (TPC) in women with suboptimal stage III (residual tumour >1 cm) or stage IV ovarian cancer to evaluate the survival rate and toxicities. Methods: Eligible for the study were patients aged at least 18 years old with histological/ cytological diagnosis of FIGO stages III (residual tumour P1 cm after primary surgery) – IV epithelial ovarian cancer. Patients were randomized to iv PC on day 1, every 21 days or iv topotecan daily for three days and PC on day 3, every 21 days. Results: The intention to treat population was made of 326 patients in total, 170 in the PC group and 156 in the TPC group. The life table estimates of survival probabilities at one, three and five years were, respectively, 0.94 (95% CI: 0.88–0.97), 0.53 (95% CI: 0.44–0.62) and 0.32 (95%CI: 0.23–0.42) in the PC group, and 0.92 (95% CI: 0.86–0.95), 0.52 (95% CI: 0.42–0.61), and 0.32(95%CI: 0.22–0.43) in the TPC group (log-rank test at 5 years: ns). The results of the survival analysis based on Cox regression model showed no statistically significant differences between groups (p-value: ns). The number of subjects with at least one event with possible relationship to study medication was 151 (88.8%) in the PC group and 139 (89.1%) in the TPC group (p = ns). Results: In the PC group, 79 patients (23.6%) experienced at least one Adverse Event (AE) graded as severe and 16 patients (4.8%) at least one life-threatening AE, whilst in the TPC group, the number of patients who presented at least one severe or life-threatening AE was 86 (24%) and 37 (10.3%), respectively. Conclusion: The results of the present study show that the addition of topotecan to a standard paclitaxel/carboplatin regimen in the treatment of advanced epithelial ovarian cancer did not result in significant advantages in terms of survival rate. A slightly worse toxicity profile for TPC was observed
Carboplatin; Ovarian cancer treatment; Paclitaxel; Survival; Topotecan
Settore MED/40 - Ginecologia e Ostetricia
Article (author)
File in questo prodotto:
File Dimensione Formato  
Paclitaxel carboplatin versus topotecan paclitaxel carboplatin.pdf

accesso aperto

Tipologia: Publisher's version/PDF
Dimensione 543.04 kB
Formato Adobe PDF
543.04 kB Adobe PDF Visualizza/Apri
Paclitaxel carboplatin versus topotecan paclitaxel carboplatin.pdf

accesso aperto

Tipologia: Publisher's version/PDF
Dimensione 543.04 kB
Formato Adobe PDF
543.04 kB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/2434/153337
Citazioni
  • ???jsp.display-item.citation.pmc??? 13
  • Scopus 38
  • ???jsp.display-item.citation.isi??? 34
social impact